AChR and TrkB: Potential Drug Targets (P6848)

Target Name: Acetylcholine Receptors (Nicotinic) (nAChR)

NCBI ID: P6848

Acetylcholine Receptors (Nicotinic) (nAChR)

Other Name(s): Neuronal acetylcholine receptors | nAChR | NACHR

AChR and TrkB: Potential Drug Targets

Acetylcholine receptors (AChR) are a family of neurotransmitter receptors that play a crucial role in neural function and communication. They are involved in a wide range of physiological processes, including muscle contractions, neurotransmitter release, and pain perception. The nicotinic acid (NAChR) subtype of AChR is a family of G protein-coupled receptors that are known for their role in modulating neural activity and behavior.

Drugs that target AChR have the potential to treat a wide range of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, chronic pain, and anxiety disorders. Therefore, the study of AChR and its potential drug targets is an area of great interest and significance.

AChR: Structure and Function

AChR are a family of G protein-coupled receptors that were first identified in the 1970s. They are characterized by a long, flexible cytoplasmic tail that is involved in the formation of homophilic interactions with other G protein-coupled receptors. The nicotinic acid (NAChR) subtype of AChR is a specific type of AChR that is involved in modulating neural activity and behavior.

AChR are involved in a wide range of physiological processes, including but not limited to:

* Muscle contractions: AChR are involved in the regulation of muscle contractions and the control of muscle relaxation.
* Neurotransmitter release: AChR are involved in the release of neurotransmitters, including dopamine, serotonin, and GABA.
* Pain perception: AChR are involved in the modulation of pain perception and the regulation of pain modulatory systems.
* Cell survival: AChR are involved in the regulation of cell survival and cell death.

Drugs that target AChR have the potential to treat a wide range of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, chronic pain, and anxiety disorders. For example, the nicotine replacement therapy (NRT) for smoking cessation is a well-known example of a drug that targets AChR. NRT works by increasing the levels of nicotine in the brain, which can activate AChR and cause a decrease in the activity of other G protein-coupled receptors, including those involved in pain perception and cell survival.

AChR antagonists have been shown to be effective in treating various psychiatric and neurological disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders. For example, research has shown that AChR antagonists can reduce the symptoms of Alzheimer's disease, including cognitive decline and memory loss, in animal models of the disease. Similarly, AChR antagonists have been shown to be effective in treating anxiety disorders by reducing the activity of AChR and modulating the activity of other G protein-coupled receptors, including those involved in pain perception and cell survival.

AChR: Potential Drug Targets

Despite the potential benefits of AChR antagonists, there are still several drug targets that have not been fully explored. One of the most promising targets is the interaction between AChR and the protein known as TrkB. TrkB is a G protein-coupled receptor that is involved in the regulation of neurotransmitter release and cell survival. The interaction between AChR and TrkB has been shown to play a role in the modulation of neural activity and behavior.

Another potential drug target for AChR is the interaction with the protein known as FAK. FAK is a non-muscle protein that is involved in the regulation of cell survival and cytoske

Protein Name: Acetylcholine Receptors (Nicotinic) (nAChR) (nonspecified Subtype)

The "Acetylcholine Receptors (Nicotinic) (nAChR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Acetylcholine Receptors (Nicotinic) (nAChR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets